Eli Lilly has entered into a multi-year research and licensing agreement with Nimbus Therapeutics to discover and develop novel oral treatments for obesity and related metabolic diseases using artificial intelligence–driven target identification and drug design. Under the deal, Lilly will fund Nimbus’s discovery efforts and, upon nomination of clinical candidates, will receive exclusive rights to global development and commercialization. The collaboration leverages Nimbus’s machine-learning platform to accelerate lead optimization and is expected to advance at least two programs into IND-enabling studies over the next three years.

Lilly’s market value has climbed to approximately $960 billion, driven by its dual-indication GLP-agonist tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. In the most recent quarter, combined sales of these two brands exceeded $10 billion, contributing to a 54 percent year-over-year increase in total revenue. Over the past three years, Lilly’s share price has nearly tripled as investors have rewarded the blend of pharmaceutical safety and rapid growth, positioning the company on the cusp of joining the exclusive $1 trillion club.

In parallel developments, Arrowhead Pharmaceuticals reported that its RNA interference candidate ARO-INHBE doubled average weight loss and tripled fat reduction when administered alongside Lilly’s tirzepatide in a mid-stage trial, highlighting the potential for combination regimens. Lilly’s own oral weight-loss candidate, currently under regulatory review, is designed to offer efficacy without stringent dietary restrictions—a potential advantage over rival offerings. With head-to-head data showing superior efficacy of Zepbound versus Novo Nordisk’s Wegovy and a robust late-stage pipeline, Lilly is well positioned to extend its leadership in the fast-growing obesity market, which analysts forecast will approach $100 billion by 2030.